Availability Of Eaps For Terminally Ill Patients

1214 Words Mar 31st, 2016 5 Pages
Availability of EAPs for Terminally Ill Patients
Terminally ill patients are often deprived access to experimental drugs as a result of federal government policies and regulations. Without access to these drugs, patients lose the opportunity to improve their current medical condition. Members of the scientific community also lose the opportunity to collect additional data that could possibly lead to scientific breakthroughs. While they are the ones affected the most, terminally ill patients are not the only ones lacking access to experimental drugs. Chronically ill patients could also benefit from easier access. The current government regulations need to be re-examined to determine whether they are inhibiting research and the medical treatment of patients in need.
The Food and Drug Administration (FDA) regulates which drugs are approved for public use. Before the FDA approves a drug it must go through three phases of human clinical trials (Tirrell). Phase 1 trials are usually open to only 20-80 patients and are used to determine what the drug’s most common side effects are (Tirrell). Hundreds of patients are involved in Phase 2 trials which are used to determine whether the drug works for a particular disease or condition (Tirrell). Thousands of patients are involved in Phase 3 trials which are used to gather more information on the effectiveness and safety (Tirrell). They also help determine the best dosages of a drug and the effects of the drug when paired with other drugs…
Open Document